COVID-19 Pandemic
This table (“dashboard”) shows the applications received by Swissmedic for the authorisation (or authorisation extension in the case of vaccines) for COVID-19 vaccines and therapeutic agents against COVID-19 and the current status of the authorisation procedures.
On this page you’ll find answers to frequently asked questions about mRNA vaccines.
All about the vaccines - briefly and concisely explained
Vaccines: Rapid solution for new diseases?
Swismedic - The way a vaccination works
How an mRNA vaccine works
How a vector vaccine works?
How a protein vaccine works
How is the safety of vaccines monitored?
Communication regarding COVID-19
18.05.2022
Swissmedic is reviewing application from Moderna Switzerland GmbH
13.05.2022
Swissmedic approves application for indication extension of Spikevax® for children 6 years and older
06.05.2022
15,228 reports of suspected adverse vaccination reactions evaluated
01.05.2022
Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3
01.05.2022
Clarifications on the prioritisation and fast-tracking of pandemic medicinal products and on the patient information requirements
20.04.2022
New shelf life at ultra-low temperature
20.04.2022
New shelf life at ultra-low temperature
13.04.2022
Protein-based vaccine from manufacturer Novavax authorised in Switzerland
12.04.2022
The Agency for Therapeutic Products has reviewed the application and approved the extension
08.04.2022
14,624 reports of suspected adverse vaccination reactions evaluated
